Advances in Diabetes Treatment - Once-Weekly Insulin

The increasing incidence of type 2 diabetes and of health consequences related to complications from inadequate glycemic control is of major concern, even in the midst of a worldwide pandemic. Despite the introduction of new adjunctive medicines, recombinant insulins, and the ability to monitor blood glucose in real time, treatment for diabetes remains less than ideal.(1) Data from the National Health and Nutrition Examination Survey (NHANES) indicate that the mean glycated hemoglobin level for adults with diabetes in the United States dropped to 7.2% in 2016; however, the percentage of patients in whom a target level of less than 7.0% . . .